Technical Articles

This article systematically elaborates on the molecular structural characteristics of HER3 as a unique member of the HER protein family and the biological basis of its lack of kinase activity, analyzes its important role in the HER2 oncogenic mechanism and the mechanisms by which its overexpression leads to resistance in targeted therapies, reviews the challenges in the clinical translation of HER3-targeting monoclonal antibodies, and on this basis, introduces the application value of HER3 recombinant proteins in drug development.